← Leaderboards
Aditi Shastri
Albert Einstein College Of Medicine
$2,374,931
Attributed
$3,449,861
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,149,861 · 1
FDA$1,300,000 · 1
By mechanism
R01$3,449,861 · 2
Top collaborators
- Sofiya Milman2 shared
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- Sofiya Milman$8,537,228
- Joe Verghese$39,214,466
- Aviv Bergman$2,419,438
- Derek Major Huffman$7,446,355
- Clyde Schechter$2,016,358
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposAge-Related DiseaseBiologicalAging RelatedCardiovascular DiseasesAreaAgingBiological FactorsBiologyBlood CellsDysmyelopoietic SyndromesCentenarianClinical PhenotypeClonal EvolutionAge RelatedClonal Hematopoietic Stem CellCognitive FunctionCohortCollegeComparison ControlComplexDna MethylationAcute Myelocytic LeukemiaEpidemiology
Grant awards (4)
CH in Aging and Exceptional Longevity$1,064,072
R01 · FY2025 · AG · contact PI
"A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML."$650,000
R01 · FY2025 · FD · contact PI
CH in Aging and Exceptional Longevity$1,085,789
R01 · FY2024 · AG · contact PI
"A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML."$650,000
R01 · FY2023 · FD · contact PI